{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:42:05Z","timestamp":1783773725806,"version":"3.55.0"},"reference-count":18,"publisher":"SAGE Publications","issue":"s1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2024,8,20]]},"abstract":"<jats:p>Background: Examination of Alzheimer\u2019s disease (AD) related biomarkers among diverse communities has remained limited. Objective: The aim of this study was to expand on prior work to provide a characterization of ptau181 among a diverse community sample. Consideration was taken regarding the impact of comorbidities on ptau181 levels including medical. Methods: 3,228 (n\u200a=\u200a770 African American [AA], n\u200a=\u200a1,231 Hispanic, and n\u200a=\u200a1,227 non-Hispanic white [NHW]) Health and Aging Brain Study- Health Disparities (HABS-HD) participants were included in this study. ANCOVAs were conducted to examine differences in ptau181 levels across race and ethnic groups. Violin plots were also generated stratified by APOE \u025b4 carrier status, Amyloid PET positivity status, medical comorbidity (hypertension, dyslipidemia, chronic kidney disease [CKD], and diabetes) and by cognitive diagnosis. Results: Ptau181 levels were found to differ between Hispanics and NHW after covarying for age, sex, and APOE \u025b4 status. Amyloid PET positivity was associated with higher ptau181 levels across all groups. APOE \u025b4 positivity status was only significantly associated with ptau181 levels among AAs. Across all race and ethnic groups, those with a diagnosis of CKD had higher levels of ptau181. When stratified by cognitive diagnosis, cognitively unimpaired Hispanics had higher ptau181 if they also had a diagnosis of CKD or diabetes. p-values \u22640.01. Conclusions: Differences in ptau181 levels were shown in a diverse community sample. Medical comorbidities had a differing effect on ptau181 levels particularly among Hispanics even without cognitive impairment. Findings support the need for future work to consider comorbid conditions when examining the utility of ptau181.<\/jats:p>","DOI":"10.3233\/jad-240633","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T10:58:44Z","timestamp":1724151524000},"page":"S63-S73","source":"Crossref","is-referenced-by-count":10,"title":["Characterization of Ptau181 Among a Diverse Community-Based Cohort: A HABS-HD Study"],"prefix":"10.1177","volume":"100","author":[{"given":"Melissa E.","family":"Petersen","sequence":"first","affiliation":[{"name":"Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA"},{"name":"Deparment of Family Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the HABS-HD Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA"},{"name":"Deparment of Family Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Hall","sequence":"additional","affiliation":[{"name":"Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA"},{"name":"Deparment of Family Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Julovich","sequence":"additional","affiliation":[{"name":"Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[{"name":"Keck School of Medicine of USC, Alzheimer\u2019s Therapeutic Research Institute, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin L.","family":"Meeker","sequence":"additional","affiliation":[{"name":"Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA"},{"name":"Deparment of Family Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Phillips","sequence":"additional","affiliation":[{"name":"Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Large","sequence":"additional","affiliation":[{"name":"Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beau M.","family":"Ances","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sid E.","family":"O\u2019Bryant","sequence":"additional","affiliation":[{"name":"Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA"},{"name":"Deparment of Family Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-240633_ref1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/jnnp-2022-330540","article-title":"Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function","volume":"94","author":"Lehmann","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-240633_ref2","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"key":"10.3233\/JAD-240633_ref3","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat Med"},{"key":"10.3233\/JAD-240633_ref4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13195-021-00802-x","article-title":"Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer\u2019s disease","volume":"13","author":"Tissot","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-240633_ref5","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/alz.12301","article-title":"Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study","volume":"17","author":"Brickman","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240633_ref6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/alz.13456","article-title":"Plasma Alzheimer\u2019s biomarkers and brain amyloid in Hispanic and non-Hispanic older adults","volume":"20","author":"Asken","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240633_ref7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240633_ref8","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/alz.13722","article-title":"The Bio-Hermes Study: Biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer\u2019s disease","volume":"20","author":"Mohs","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240633_ref9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40035-023-00365-x","article-title":"Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints","volume":"12","author":"Lu","year":"2023","journal-title":"Transl Neurodegener"},{"key":"10.3233\/JAD-240633_ref10","doi-asserted-by":"crossref","first-page":"e12502","DOI":"10.1002\/dad2.12502","article-title":"Predicting amyloid PET positivity using plasma p-tau181 and other blood-based biomarkers","volume":"15","author":"Kwon","year":"2023","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-240633_ref11","doi-asserted-by":"crossref","first-page":"e1402","DOI":"10.1212\/WNL.0000000000207675","article-title":"Association of plasma biomarkers of Alzheimer disease with cognition and medical comorbidities in a biracial cohort","volume":"101","author":"Ramanan","year":"2023","journal-title":"Neurology"},{"key":"10.3233\/JAD-240633_ref12","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1002\/alz.13318","article-title":"Longitudinal blood biomarker trajectories in preclinical Alzheimer\u2019s disease","volume":"19","author":"Yakoub","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240633_ref13","doi-asserted-by":"crossref","first-page":"e12315","DOI":"10.1002\/dad2.12315","article-title":"Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI","volume":"14","author":"Windon","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-240633_ref14","first-page":"637","article-title":"Clinical Dementia Rating (CDR)","volume":"24","author":"Berg","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"10.3233\/JAD-240633_ref15","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","article-title":"Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: A Texas Alzheimer\u2019s research consortium study","volume":"65","author":"O\u2019Bryant","year":"2008","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-240633_ref16","doi-asserted-by":"crossref","first-page":"e12202","DOI":"10.1002\/dad2.12202","article-title":"The Health & Aging Brain among Latino Elders (HABLE) study methods and participant characteristics","volume":"13","author":"O\u2019Bryant","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-240633_ref17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/alz.12668","article-title":"Quantification of amyloid beta and tau PET without a structural MRI","volume":"19","author":"Landau","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-240633_ref18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jalz.2014.08.099","article-title":"Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer\u2019s disease research","volume":"11","author":"O\u2019Bryant","year":"2015","journal-title":"Alzheimers Dement"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-240633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:58:48Z","timestamp":1777370328000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-240633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":18,"journal-issue":{"issue":"s1"},"URL":"https:\/\/doi.org\/10.3233\/jad-240633","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]}}}